JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Alcon Inc

Suletud

SektorTervishoid

84.66 -1.24

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.49

Max

85.68

Põhinäitajad

By Trading Economics

Sissetulek

76M

350M

Müük

-29M

2.5B

P/E

Sektori keskmine

39.031

34.393

Dividenditootlus

0.38

Kasumimarginaal

14.153

Töötajad

25,000

EBITDA

-226M

463M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+24.44% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.38%

2.54%

Järgmine tulemuste avaldamine

19. aug 2025

Turustatistika

By TradingEconomics

Turukapital

3.6B

44B

Eelmine avamishind

85.9

Eelmine sulgemishind

84.66

Uudiste sentiment

By Acuity

50%

50%

162 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Alcon Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. aug 2025, 10:10 UTC

Omandamised, ülevõtmised, äriostud

Alcon to Buy Staar Surgical for $1.5 Billion

14. mai 2025, 15:56 UTC

Tulu
Suurimad hinnamuutused turgudel

Alcon Shares Fall After Lowering 2025 Outlook

26. märts 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24. märts 2025, 12:36 UTC

Omandamised, ülevõtmised, äriostud

Alcon to Buy Lensar in Deal Worth Up to $430 Million

8. aug 2025, 13:40 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Staar Surgical's Top Holder Questions Deal -- Market Talk

5. aug 2025, 05:07 UTC

Omandamised, ülevõtmised, äriostud

Alcon Deal Puts STARR Equity Value at Approximately $1.5 Billion. >ALC.EB

5. aug 2025, 05:07 UTC

Omandamised, ülevõtmised, äriostud

Alcon Will Purchase All Outstanding Shares of STAAR Common Stock for $28 Per Share in Cash >ALC.EB

5. aug 2025, 05:07 UTC

Omandamised, ülevõtmised, äriostud

Alcon Deal Represents 51% Premium to Closing Price of STAAR Common Stock on Aug. 4 >ALC.EB

5. aug 2025, 05:07 UTC

Omandamised, ülevõtmised, äriostud

Alcon Agrees to Acquire STAAR Surgical >ALC STAA

5. aug 2025, 05:01 UTC

Omandamised, ülevõtmised, äriostud

Alcon Agrees To Acquire STAAR Surgical >ALC STAA

7. juuli 2025, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Alcon To Acquire LumiThera And Its Photobiomodulation Device For The Treatment Of Early And Intermediate Dry Age-Related Macular Degeneration (AMD) >ALC

30. mai 2025, 06:32 UTC

Market Talk
Tulu

Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

22. mai 2025, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

13. mai 2025, 20:32 UTC

Tulu

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. mai 2025, 20:31 UTC

Tulu

Alcon 1Q Sales $2.45B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q Rev $2.47B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q EPS 70c >ALC.EB

8. apr 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

26. märts 2025, 21:55 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26. märts 2025, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26. märts 2025, 20:32 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26. märts 2025, 20:32 UTC

Omandamised, ülevõtmised, äriostud

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26. märts 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26. märts 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26. märts 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26. märts 2025, 20:30 UTC

Omandamised, ülevõtmised, äriostud

Alcon Acquires Majority Interest in Aurion Biotech

24. märts 2025, 12:21 UTC

Omandamised, ülevõtmised, äriostud

Alcon to Buy Lensar in Deal Worth Up to $430M

24. märts 2025, 12:05 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24. märts 2025, 12:05 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24. märts 2025, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

Võrdlus sarnastega

Hinnamuutus

Alcon Inc Prognoos

Hinnasiht

By TipRanks

24.44% tõus

12 kuu keskmine prognoos

Keskmine 106.71 USD  24.44%

Kõrge 123.933 USD

Madal 84 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Alcon Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

12

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

95.77 / 97.61Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

162 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.